[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562523":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":56,"collaborators":18,"id":59,"slug":18,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":18,"enrollmentInfo":67,"targetDuration":18,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":44,"whyStopped":18,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 2","EXPERIMENTAL","This group undergoes FAPi-PET CT imaging",[13],"Diagnostic Test: Fibroblast Activation Protein Inhibitor",{"label":15,"type":16,"description":17,"interventionNames":18},"Group 1","NO_INTERVENTION","Does not undergo a FAPi scan",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIAGNOSTIC_TEST","Fibroblast Activation Protein Inhibitor","PET CT imaging using the fibroblast activation protein inhibitor tracer",[9],[26],"FAPi PET CT scan",[28],{"name":29,"affiliation":30,"role":31},"Mark Lowenberg, MD PhD","Amsterdam UMC, location VUmc","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},"Dalia A Lartey, MD","CONTACT","+31205668160","d.a.lartey@amsterdamumc.nl",{"name":39,"role":35,"phone":36,"phoneExt":18,"email":40},"Kelly van Wijnbergen, Msc","k.vanwijnbergen@amsterdamumc.nl",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":18},"Amsterdam UMC","RECRUITING","Amsterdam","North Holland","1081BT","Netherlands","NL",{"type":51,"coordinates":52},"Point",[53,54],4.88969,52.37403,{"lat":54,"lon":53},{"type":31,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Dalia Lartey","Drs","100562523",false,"NCT06604273","Unravelling Intestinal Fibrosis in Ulcerative Colitis","INTERACT","Inclusion Criteria:\n\n* Adults with confirmed diagnosis of UC - Group 1 criterion: ≥18 years of age regardless of gender\n* Group 2 criterion: ≥30 years of age for males and ≥40 years of age for females\n* Active disease confirmed by endoscopy (endoscopic Mayo score ≥ 2)\n* Indication to start treatment with filgotinib\n\nAND one of the following criteria:\n\n* Active disease confirmed by intestinal ultrasound (BWT \\> 3 mm in at least one bowel segment and at least one other pathological IUS parameter) or\n* Increased CRP (\\>5 mg\u002FL) and\u002For fecal calprotectin levels (\\>250 mg\u002Fkg)\n\nExclusion Criteria:\n\n* Pregnancy\n* Unable to provide informed consent\n* Colorectal carcinoma or high-grade dysplasia","ALL","18 Years",{"count":68,"type":69},10,"ESTIMATED","INTERVENTIONAL",[72,73],"PHASE2","PHASE3","The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET\u002FCT imaging",[76,77,22],"Ulcerative Colitis (UC)","Inflammatory Bowel Disease (IBD)",[79,80,81,82,83],"PET CT","FAPI","IBD","Ulcerative colitis","Filgotinib","2024-09-17",{"date":86,"type":87},"2024-09-19","ACTUAL",{"date":89,"type":87},"2024-04-03",{"date":91,"type":69},"2026-04-03",{"name":5,"class":6},1]